Strategic partnerships Precirix has a history of collaborations with Eckert & Ziegler and Orchestra Life Sciences to enhance radiopharmaceutical development and access to radioisotopes, signaling openness to partner-driven sales and co-development opportunities.

Clinical focus With CAM-H2 in Phase I/II for HER2-positive tumors and a theranostic platform, target oncology customers may value licensing or collaboration for imaging-therapy pairs and companion diagnostics in HER2 cancers.

Academic access Launch of the CAM-FAP-Ga-68 Academic Access Program indicates a conduit to academic and translational centers, presenting a pathway for early-stage clinical collaborations and proof-of-concept partnerships.

Growth potential Recent leadership change with a new CEO and ongoing pipeline expansion suggest active corporate development and readiness for strategic financing or joint ventures to scale radiopharmaceutical programs.

Regional focus Based in Brussels with a Lean team size and a European footprint, there are near-term opportunities to engage European clinical centers, CROs, and radiopharma distributors looking for regionally partnered programs.